Herceptin and Avastin.

Among other things,, could Avastin obtain the potential in the treatment of metastatic breast cancer by unexpected safety, efficacy or manufacturing issues, additional time for data analysis and decision making, FDA actions, the failure of the FDA approval, competition, reimbursement prices , affects the ability to supply, product or product withdrawal. Please note also related regular reports filed with the Securities Genentech and Exchange Commission.

FU-based chemotherapy The approval was based on data from two studies. The pivotal trial was a large, placebo – controlled, randomized study, that an improvement in median survival of patients treated with Avastin plus IFL for about five months of chemotherapy showed, compared with patients treated with the IFL chemotherapy alone . The addition of Avastin to improved survival rate of 52 % .. The FDA approved Avastin on 26 February 2004 as a first-line treatment of metastatic colorectal cancer in combination with intravenous 5.– Cold electrons technology is opening up a new world of imaging – it is the first trial his full potential its full potential, he said.. Our with cold with cold electronic and our new technology, we shall be in a position take a snapshot a snapshot of the entire sample a reduce the exposure time to a trillionth of a second, he said for extracting used the team of associate Professor Scholten laser cool atoms to a few millionths a degree above absolute zero, and will for directing a beam out of very cold electronic out.

Associate Professor Robert Scholten out of the University’s School of Physics and the CXS , said the new cold electron source gave prospective advances for electron microscopy imaging of of the nuclear or nano the real-world applications in a variety of industries, including health care are has. – Enhanced nano imaging to these cold Provided are will allow us to develop improved drugs to more targeted therapies the to support better visibility of structure of membrane protein does work in the directed based drug design.